A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Pf-05161704 After Administration Of Multiple Escalating Oral Doses In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2011
At a glance
- Drugs PF 5161704 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 10 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Sep 2010 New trial record